Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis

Note: This is the most current version of the guidelines (June 2013). The March 2014 MMWR notice refers to this version.

(PDFpdf icon – 492K)

Table of Contents

• Introduction
• Methodology for Preparation of these Guidelines
• The Role of Rifamycins in Tuberculosis Treatment
• Managing Drug Interactions with Antiretrovirals and Rifampin
• Managing Drug Interactions with Antivirals and Rifabutin
• Treatment of Latent TB Infection with Rifampin or Rifapentine
• Treating Pregnant Women with Tuberculosis and HIV Co-infection
• Treating Children with HIV-associated Tuberculosis
• Co-treatment of Multidrug-resistant Tuberculosis and HIV
• Limitations of these Guidelines
• HIV-TB Drug Interaction Guideline Development Group
• References
• Table 1a. Recommendations for regimens for the concomitant treatment of tuberculosis and HIV infection in adults
• Table 1b.Recommendations for regimens for the concomitant treatment of tuberculosis and HIV infection in children
• Table 2a. Recommendations for co-administering antiretroviral drugs with RIFAMPIN in adults
• Table 2b. Recommendations for co-administering antiretroviral drugs with RIFAMPIN in children
• Table 3. Recommendations for co-administering antiretroviral drugs with RIFABUTIN in adults